- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DBV Technologies (DBVT)
DBV Technologies stock price live, this page displays NASDAQ DBVT stock exchange data. View the DBVT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the DBV Technologies real time stock price chart below.
What Is the DBV Technologies Stock Price Today?
The DBV Technologies stock price today is 7.980.
What Is the Stock Symbol for DBV Technologies?
The stock symbol for DBV Technologies is "DBVT."
What Stock Exchange Does DBV Technologies Trade On?
DBV Technologies is listed and trades on the NASDAQ stock exchange.
Is DBV Technologies a Good Stock to Buy?
Determining whether DBV Technologies—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DBVT quote. (ISIN: US23306J3095)
What Is the DBV Technologies Stock Price Today?
The DBV Technologies stock price today is 7.980.
What Is the Stock Symbol for DBV Technologies?
The stock symbol for DBV Technologies is "DBVT."
What Stock Exchange Does DBV Technologies Trade On?
DBV Technologies is listed and trades on the NASDAQ stock exchange.
Is DBV Technologies a Good Stock to Buy?
Determining whether DBV Technologies—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DBVT quote. (ISIN: US23306J3095)
7.980
+0.070(+0.88%)
Closed·
After Hours
7.720-0.260(-3.258%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.651
8.440
52 wk Range
2.205
8.500
DBVT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.6518.440
52 wk Range
2.2058.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DBVT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
23.669
Upside
+196.61%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
DBV Technologies Company Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
DBV Technologies SWOT Analysis
Peanut Patch Promise | DBV Technologies' Viaskin Peanut shows potential in treating food allergies, with encouraging long-term efficacy data from clinical trials for young children |
Regulatory Tightrope | Explore DBV's ongoing interactions with the FDA, addressing crucial questions about patch wear time and study protocols to derisk the approval pathway |
Financial Crossroads | With a cash runway until Q1 2025, DBV faces funding challenges. Analysts project potential annual U.S. revenue of $2 billion, with a $10 price target |
Market Positioning | Delve into DBV's competitive edge in the food allergy treatment market, leveraging Viaskin Peanut's safety profile and convenience for young patients |
DBV Technologies Earnings Call Summary for Q2/2024
- DBV Technologies advances Viaskin Peanut trials; VITESSE Phase 3 enrollment for ages 4-7 to complete by Q3 end
- Net loss of $60.5M in H1 2024; cash runway extended to Q1 2025 through cost-saving measures
- FDA feedback pending on labeling approach for toddlers aged 1-3; EPITOPE trial year 3 results expected later in 2024
- Operating expenses at $65M, including $24M non-recurring costs; cash used in operations totaled $70M
- Company optimistic about FDA agreement on labeling; emphasizes patient experience data importance
Last Updated: 01/08/2024, 08:54 am
Read Full TranscriptCompare DBVT to Peers and Sector
Metrics to compare | DBVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDBVTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −1.1x | −0.5x | |
PEG Ratio | 0.03 | 0.03 | 0.00 | |
Price/Book | 7.5x | 2.3x | 2.6x | |
Price / LTM Sales | 49.8x | 4.9x | 2.9x | |
Upside (Analyst Target) | 197.2% | 69.9% | 66.3% | |
Fair Value Upside | Unlock | 16.9% | 10.2% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 23.669
(+196.61% Upside)
Earnings
Latest Release
Jul 29, 2024
EPS / Forecast
-- / -0.19
Revenue / Forecast
-- / 2.31M
People Also Watch
FAQ
What Is the DBV Technologies (DBVT) Stock Price Today?
The DBV Technologies stock price today is 7.98
What Stock Exchange Does DBV Technologies Trade On?
DBV Technologies is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for DBV Technologies?
The stock symbol for DBV Technologies is "DBVT."
What Is the DBV Technologies Market Cap?
As of today, DBV Technologies market cap is 206.76M.
What is DBV Technologies Earnings Per Share?
The DBV Technologies EPS is -1.17.
From a Technical Analysis Perspective, Is DBVT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.